<DOC>
	<DOCNO>NCT00413049</DOCNO>
	<brief_summary>This study evaluate safety efficacy fix combination valsartan/amlodipine adult patient mild moderate hypertension</brief_summary>
	<brief_title>Efficacy/Safety Valsartan Plus Amlodipine Amlodipine Alone Patients With Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Inclusion criterion Male female outpatient ≥ 18 year &lt; 86 year Patients essential hypertension measure calibrated mercury sphygmomanometer ( prefer ) aneroid device mercury sphygmomanometer available . At Visit 1 , patient treat antihypertensive medication MSDBP ≥ 95 mmHg &lt; 110 mmHg ; patient treat antihypertensive medication MSDBP &lt; 110 mmHg . At Visit 2 , patient must MSDBP ≥ 95 mmHg &lt; 110 mmHg . At Visit 3 , patient must MSDBP ≥ 90 mmHg &lt; 110 mmHg . Patients eligible able participate study , consent purpose nature investigation clearly explain ( write inform consent ) . Exclusion criterion Severe hypertension ( MSDBP ≥ 110 mmHg and/or MSSBP ≥ 180 mmHg ) . In case patient one antihypertensive drug whether fix free combination , investigator consider efficacy strength active ingredient order determine patient could safely remove antihypertensive treatment . Known suspected contraindication , include history allergy hypersensitivity angiotensin receptor blocker ( ARB ) , calcium channel blocker ( CCB ) , drug similar chemical structure . Administration agent indicate treatment hypertension Visit 1 exception agent require tapering . Inability discontinue prior antihypertensive medication safely maximum period 28 day prior Visit 2 , require protocol . History hypertensive encephalopathy , cerebrovascular accident transient ischemic attack , myocardial infarction type revascularization . Malignant hypertension . All patient Type 1 diabetes mellitus patient Type 2 diabetes mellitus well control base investigator 's clinical judgment . Patients treat diabetes mellitus satisfactory metabolic control . Type 2 diabetic patient take oral antidiabetic medication stable dose least 4 week prior Visit 1 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive human chorionic gonadotropin ( hCG ) laboratory test ( &gt; 5 mIU/ml ) . Women childbearing potential ( WOCBP ) , define woman physiologically capable become pregnant , include woman whose career , lifestyle , sexual orientation preclude intercourse male partner woman whose partner sterilize vasectomy mean , UNLESS meet follow definition postmenopausal : 12 month natural ( spontaneous ) amenorrhea 6 month spontaneous amenorrhea serum follicle stimulate hormone ( FSH ) level &gt; 40 mIU/m 6 week postsurgical bilateral oophorectomy without hysterectomy OR use one follow acceptable method contraception : surgical sterilization ( e.g. , bilateral tubal ligation , vasectomy ) , doublebarrier method ( double combination : intrauterine device [ IUD ] , male female condom spermicidal gel , diaphragm , sponge , cervical cap ) . Acceptable method contraception include total abstinence discretion investigator case age , career , lifestyle , sexual orientation patient ensure compliance . Reliable contraception maintain throughout study 7 day study drug discontinuation . Periodic abstinence ( eg , calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception . Hormonal contraceptive use disallow . History heart failure Grade IIIV accord New York Heart Association ( NYHA ) classification . Second third degree heart block without pacemaker . Concomitant potentially life threaten arrhythmia symptomatic arrhythmia . Angina pectoris type , include unstable angina pectoris . Clinically significant valvular heart disease . Evidence secondary form hypertension , include limited following : coarctation aorta , hyperaldosteronism , unilateral bilateral renal artery stenosis , Cushing disease , pheochromocytoma , polycystic kidney disease . Known moderate malignant retinopathy , define : moderate ( retinal sign hemorrhage , microaneurysm , cottonwool spot , hard exudate , combination thereof ) malignancy ( sign moderate retinopathy plus swelling optic disk ) . Evidence hepatic disease determine one following : aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) value great two time upper limit normal Visit 1 , history hepatic encephalopathy , history esophageal varix , history portocaval shunt . Evidence renal impairment determine anyone following : serum creatinine &gt; 1.5 time upper limit normal Visit 1 , history dialysis , history nephrotic syndrome . History clinically significant allergy include asthma , and/or multiple drug allergy . Any surgical medical condition potential significantly alter absorption , distribution , metabolism , excretion drug include limited following : history major gastrointestinal tract surgery gastrectomy , gastroenterostomy , bowel resection , gastric bypass , gastric stapling , gastric banding , currently active active inflammatory bowel syndrome within 12 month prior Visit 1 , currently active gastritis , ulcer , gastrointestinal/rectal bleeding , urinary tract obstruction regard clinically meaningful investigator . Any surgical medical condition , opinion investigator Novartis monitor , place patient high risk his/her participation study , likely prevent patient comply requirement study complete trial period . Volume depletion base investigator 's clinical judgment use vital sign , skin turgor , moistness mucous membrane , laboratory value . Any chronic inflammatory condition require chronic antiinflammatory therapy . History malignancy organ system , treat untreated , within past 5 year whether evidence local recurrence metastasis , exception localize basal cell carcinoma skin . History drug alcohol abuse within last 2 year . Use investigational drug time enrollment , within 30 day 5 halflives enrollment , whichever longer . Inability communicate comply study requirement include unwillingness inability provide inform consent . Persons directly involved execution protocol . History noncompliance medical regimen , unwillingness comply study protocol . Currently take prohibit concomitant medication ( ) list inability/unwillingness discontinue entire study period . Any severe , lifethreatening disease within past five year . Arm circumference &gt; 42 cm patient participate ambulatory blood pressure monitoring ( ABPM ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Hypertension , valsartan , amlodipine , high blood pressure</keyword>
</DOC>